Premium
Stabilising normal and mis‐sense variant α‐glucosidase
Author(s) -
Kakavanos Revecca,
Hopwood John J.,
Lang Debbie,
Meikle Peter J.,
Brooks Doug A.
Publication year - 2006
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2006.06.096
Subject(s) - enzyme , alpha glucosidase , alpha (finance) , chemistry , biochemistry , glycogen , glycogen storage disease type ii , enzyme assay , fibroblast activation protein, alpha , in vitro , glycogen storage disease , endocrinology , medicine , biology , enzyme replacement therapy , disease , construct validity , nursing , cancer , patient satisfaction
α‐Glucosidase (EC 3.2.1.3) is a lysosomal enzyme that hydrolyses α‐1,4‐ and α‐1,6‐linkages of glycogen to produce free glucose. A deficiency in α‐glucosidase activity results in glycogen storage disorder type II (GSD II), also called Pompe disease. Here, d ‐glucose was shown to be a competitive inhibitor of α‐glucosidase and when added to culture medium at 6.0 g/L increased the production of this protein by CHO‐K1 expression cells and stabilised the enzyme activity. d ‐Glucose also prevented α‐glucosidase aggregation/precipitation and increased protein yield in a modified purification scheme. In fibroblast cells, from adult‐onset GSD II patients, d ‐glucose increased the residual level of α‐glucosidase activity, suggesting that a structural analogue of d ‐glucose may be used for enzyme enhancement therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom